Domainex is first UK CRO to invest in NanoTemper’s novel Drug Discovery technology

By Dani Bancroft contact

- Last updated on GMT

Image: Trevor Perrior, CSO of Domainex.
Image: Trevor Perrior, CSO of Domainex.

Related tags: High-throughput screening

NanoTemper Technologies Gmbh has scored custom from the UK CRO Domainex Ltd., which is using its MicroScale Thermophoresis technology for speedier, “higher quality clinical candidates”.

NanoTemper Technologies is a biophysical instrument manufacturer in Munich, German with patented technology for high throughput screening of clinical candidates for a range of molecular sizes – including biologics.

Domainex is the first UK CRO to purchase and fully commission one of NanoTemper’s Monolith NT.Automated screening instruments.

Domainex is a small-molecule​ biotech and clinical services organisation in Cambridge, UK, with services such as assay development and fragment based drug-discovery (FBBD) for preclinical candidate discovery and validation.

Trevor Perrior, CSO of Domainex told Outsourcing-Pharma “This is the first MST instrument we've purchased, and we have a lot of confidence in the technique. [In fact], we’re the first people in the CRO world to invest in [NanoTemper’s] capabilities.”

Fragment screening with MST

The device uses NanoTemper’s patented Microscale thermophoresis (MST) technology, which serves as an automated alternative to Differential scanning fluorimetry​ (DSF) or NMR spectroscopy​ techniques for screening candidates.

Perrior explained that these kind of techniques tend to use up more protein when fragment screening – for example, NMR screening typically​ uses more than 10mg of protein.

MST instruments are sensitive enough that they just need 400 µg of protein.

Stefan Duhr, CEO of NanoTemper Technologies, told Outsourcing-Pharma on the phone “MST is also very flexible technology in terms of application range – [the instrument] is independent of weight changes” – ​and therefore also able to detect larger molecules and multi-protein complexes.

monolith_nmr_thermophoresis_dsf_fbbd_screening_domainex_fragment_CRO_discovery_nanotemper_technology_1
Images: The Monolith NT.Automated instrument (MO-G011) from NanoTemper Technologies Gmbh  

Efficiency

Domainex previously​ told in-PharmaTechnologist that its approach to finding leads is also 30% faster than the industry average.

With automation of the FBBD process, the speed of fragment screening can therefore be further improved using the Monolith NT. Automated device.

Perrior added “With up to 400 measurements an hour – it takes a fraction of the time compared to manual techniques.”

The instrument carries out the bulk of the screening, with hits then being confirmed using NMR or other techniques to complete validation.

“If you get 10 hits, checking each of those hits using NMR is a very manageable thing to do.”

Perrior added “All of these screening services feed into our general drug discovery services, to elaborate into clinical candidates.”

Europe, CROs and Biologics 

Stefan Duhr added “NanoTemper Technologies has a lot of customers screening for small molecules and fragments," ​such as Domainex, "but [MST technology] goes all the way up to biologics and biosimilars.”

Duhr continued, “We're seeing a lot of these kind of investments in the European CRO industry. For example, I see a lot of dynamics in the biosimilars business and an increasing need for such biophysical screening services.”

The firm already has European operations in Germany, Cambridge (UK) and Kraków.

Duhr told Outsourcing-Pharma that because many of NanoTemper’s clients are academics or working in pharmaceuticals, “we of course have situations where people request services from us." 

"But we provide the instruments. CROs are a great opportunity to access this technology.”

monolith_nmr_thermophoresis_dsf_fbbd_screening_domainex_fragment_CRO_discovery_nanotemper_technology_2
monolith_nmr_thermophoresis_dsf_fbbd_screening_domainex_fragment_CRO_discovery_nanotemper_technology_3

Related news

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars